On the other hand, the GSTO2*A424G polymorphism (rs156697) has been shown to be associated with ovarian, breast, urinary bladder, and renal cell cancers, which is in agreement with the results of our study [33,37,41,42,43]. This evidence concerns the gene GSTO2 and renal cell adenocarcinoma.